ライフサイエンスコーパス: umbilical cord blood

1 betes may have risk markers already in their umbilical cord blood.

2 = 313), single (n = 89) or double (n = 123) umbilical cord blood.

3 mmune cells from maternal blood and neonatal umbilical cord blood.

4 mature/transitional 1 B cells recovered from umbilical cord blood.

5 ibly higher after transplants of HLA-matched umbilical cord blood.

6 ineage progenitor cells (MLPC) prepared from umbilical cord blood.

7 s and measurements of stem cell potential in umbilical cord blood.

8 man LAD2 and primary mast cells derived from umbilical cord blood.

9 r (nNIF) is an inhibitor of NET formation in umbilical cord blood.

10 progenitor cells (HSPCs) derived from human umbilical cord blood.

11 ons of prenatal PFAS with DNA methylation in umbilical cord blood.

12 pairs, we analyzed natalizumab levels in the umbilical cord blood.

13 ritin levels were infant sex and ferritin in umbilical cord blood.

14 d levels of thyroid hormones in maternal and umbilical-cord blood.

15 eripheral blood (61%), bone marrow (25%), or umbilical cord blood (14%); 53% were from unrelated dono

16 (HHV-6) infection has been documented after umbilical cord blood allo-transplant in adults.

17 vailable clinical and biological advances of umbilical cord blood allogeneic stem cell transplantatio

18 Mean (+/-SD) concentrations of umbilical cord blood alpha-CEHC (30.2 +/- 28.9 nmol/L) a

19 Additional advances in the basic biology of umbilical cord blood also appear very promising in devel

20 s to collect biological specimens, including umbilical cord blood and amniotic fluid, to be made avai

21 -mobilized CD34(+) cells isolated from human umbilical cord blood and demonstrate that MPO-induced ox

22 CD161(hi) cells from umbilical cord blood and granulocyte colony stimulating

23 T cells are present in adult peripheral and umbilical cord blood and in both conventional T naive an

24 lood spots were slightly lower than those in umbilical cord blood and predicted umbilical cord blood

25 de methylation levels at 482,397 CpG loci in umbilical cord blood and retained 394,460 loci after qua

26 administered a single infusion of autologous umbilical cord blood and, as part of their clinical outc

27 ations for blood-derived (from peripheral or umbilical cord blood) and bone marrow-derived stem cells

28 d, mismatched unrelated, haploidentical, and umbilical cord blood), and compared transplantation outc

29 raft type (bone marrow, peripheral blood, or umbilical cord blood), and transplantation period (2008-

30 d RNA from fetuses with trisomies 21 and 18, umbilical cord blood, and blood from newborns with bronc

31 enrichment were measured in maternal blood, umbilical cord blood, and placental tissue when availabl

32 human placenta and levels of its ligands in umbilical cord blood, and to verify the influence of Cxc

33 ell reconstitution, especially when HSC from umbilical cord blood are used.

34 nors (URDs), either from volunteer adults or umbilical cord blood, are comparable with those from MSD

35 Consequently, the use of umbilical cord blood as a HSC source and the global inve

36 phenotypes, were compared with normal BM and umbilical cord blood as well as BM from children on enzy

37 mother's blood during the second trimester; umbilical cord blood at birth; and shed deciduous inciso

38 um of transplant centers, donor centers, and umbilical cord blood banks.

39 tion of human HSC (Lin-CD34+CD38-CD90+) from umbilical cord blood (CB) as well as the xenotransplanta

40 pluripotent stem cells (iPSCs) derived from umbilical cord blood (CB) cells and neonatal keratinocyt

41 higher in neonatal naive CD4(+) T cells from umbilical cord blood (CB) compared with naive CD4(+) T c

42 Human umbilical cord blood (CB) has attracted much attention a

43 Umbilical cord blood (CB) is a valuable source of stem c

44 ds associated with Fenton BW z-score and the umbilical cord blood (CB) lipidome.

45 They are easily isolated from umbilical cord blood (CB) or adult peripheral blood (PB)

46 the development of NK cells after intrabone umbilical cord blood (CB) transplantation in 18 adult pa

47 he restricted numbers of stem cells found in umbilical cord blood (CB), while also enhancing the cont

48 The role of umbilical cord blood (CB)-derived stem cell therapy in n

49 nctional characterization was performed from umbilical cord blood (CB).

50 ifferentiated in vitro from progenitors from umbilical cord blood (CB-EC) or adult peripheral blood (

51 roduces embryonic-like stem cells from human umbilical cord blood (CBEs) for neural differentiation u

52 -SLAM (not CD150(+)CD48(-)) cells from human umbilical cord blood CD34(+) cells as well as from human

53 Briefly, umbilical cord blood CD34(+) cells were isolated and cul

54 of human primary megakaryocytes derived from umbilical cord blood CD34(+) cells.

55 NOD-scid/gammac(-/-) mice grafted with human umbilical cord blood CD34(+) hematopoietic progenitor ce

56 Cas9 genome engineering of primary adult and umbilical cord blood CD34(+) human hematopoietic stem an

57 ling and peroxiredoxin 4 expression in human umbilical cord blood cell-mediated protection of oligode

58 Transplantation of ex vivo expanded human umbilical cord blood cells (hCB) only partially enhances

59 In vivo, systemic administration of human umbilical cord blood cells 48 h after middle cerebral ar

60 The presence of human umbilical cord blood cells also increased Akt phosphoryl

61 that the soluble factors released from human umbilical cord blood cells converge on Akt to elevate pe

62 Moreover, human umbilical cord blood cells protected striatal white matt

63 g-term repopulating ability of human CD34(+) umbilical cord blood cells.

64 ely, negated the protective effects of human umbilical cord blood cells.

65 red to FLT3/ITD(neg) cells and spared normal umbilical cord blood cells.

66 Inverse associations between maternal or umbilical cord blood concentrations of perfluorooctanoic

67 cotinine level of 10 ng/mL or more and using umbilical cord blood cotinine as the criterion standard,

68 those in umbilical cord blood and predicted umbilical cord blood cotinine levels well (beta = 0.95,

69 8 newborns delivered in 2001-2003 with known umbilical cord blood cotinine levels.

70 al blood supplies are inadequate, allogeneic umbilical cord blood could be a feasible alternative.

71 use newborn blood (NBB), equivalent to human umbilical cord blood, could be used for diabetes prevent

72 rom adult tissues, including bone marrow and umbilical cord blood, could be utilized in repair and re

73 f Plasmodium falciparum malaria parasites in umbilical cord blood denotes infection acquired antenata

74 n of mature, enucleated erythroid cells from umbilical cord blood derived CD34(+) haematopoietic prog

75 enhances the stem cell activity of cultured umbilical cord blood derived hematopoietic cells.

76 ed polyethersulfone nanofiber-expanded human umbilical cord blood-derived CD34(+) cells (henceforth C

77 nd, a human immune system was generated from umbilical cord blood-derived CD34(+) hematopoietic stem

78 EV treatment of human umbilical cord blood-derived CD34(+) HSPCs alters the ex

79 Accordingly, the treatment of umbilical cord blood-derived CD34(+) HSPCs with stimulat

80 (IL-2), combined with ex vivo expanded human umbilical cord blood-derived CD8(+) T cells, that have b

81 We transplanted lineage-depleted human umbilical cord blood-derived cells with high aldehyde de

82 We examined the effects of human umbilical cord blood-derived ECFCs and their extracellul

83 Umbilical cord blood-derived EPCs (cbEPCs) were analyzed

84 d vessels generated by peripheral blood- and umbilical cord blood-derived EPCs in a model of in vivo

85 Related results are obtained in human umbilical cord blood-derived erythroid progenitor-2 cell

86 Umbilical cord blood-derived haematopoietic stem cells (

87 In this study, we genetically modified human umbilical cord blood-derived hematopoietic stem cells (H

88 f AHR results in a marked expansion of human umbilical cord blood-derived HSPCs following cytokine st

89 We found that umbilical cord blood-derived HSPCs showed the greatest t

90 imulates human leukemic mast cells and human umbilical cord blood-derived mast cells to release newly

91 an leukemic mast cell (HMC-1) line and human umbilical cord blood-derived mast cells.

92 thors also successfully differentiated human umbilical cord blood-derived progenitor cells into CARiK

93 We characterized the dynamic adhesion of umbilical-cord-blood-derived EPCs (CB-EPCs) to surfaces

94 Although CD4(+) T cells from umbilical cord blood did not express IL-1RI, the cytokin

95 Umbilical cord blood DNA methylation was evaluated using

96 equencing was used to measure methylation in umbilical cord blood DNAs.

97 Haploidentical and umbilical cord blood donations may be valid transplant o

98 Effectiveness of double umbilical cord blood (dUCB) grafts relative to conventio

99 (RIC) was used with either unrelated double umbilical cord blood (dUCB) or HLA-haploidentical relate

100 In contrast, umbilical cord blood EPCs form normal-functioning blood

101 Thus, umbilical cord blood EPCs hold great therapeutic potenti

102 , A, and B red blood cells as well as pooled umbilical cord blood erythrocytes.

103 numbers of CD34(+) cells isolated from human umbilical cord blood, for therapeutic applications.

104 ELISA was used to quantify beta(2)GPI in umbilical cord blood from 97 neonates exposed to anti-Ro

105 Transplantation of umbilical-cord blood from unrelated donors in newborns w

106 ting NK cells after adult unrelated donor or umbilical cord blood grafting.

107 Umbilical cord blood grafts are increasingly used as sou

108 shown that NKG2C(+) NK cells from CMV naive umbilical cord blood grafts expand preferentially in rec

109 h T cell-depleted or naive T cell-containing umbilical cord blood grafts, suggesting a role for T cel

110 of engraftment, particularly in the case of umbilical cord blood grafts.

111 suggest that techniques for bone marrow and umbilical cord blood harvest may benefit from means to d

112 Umbilical-cord blood has been used as the source of hema

113 ne marrow or peripheral blood, or the use of umbilical cord blood, has decreased the risk of graft-ve

114 ) isolated from sites such as bone marrow or umbilical cord blood have been the primary means to iden

115 e and neck 28 days after undergoing a double umbilical cord blood hematopoietic stem cell transplant

116 and contrasting with what was observed with umbilical cord blood HPCs, CD34(+) HPCs from human adult

117 or potential treatment of MPS III B is human umbilical cord blood (hUCB) cell transplantation.

118 Human umbilical cord blood (HUCB) cells protect the brain agai

119 laboratory has shown that infusion of human umbilical cord blood (HUCB) cells protects striatal whit

120 Rationale: Human umbilical cord blood (hUCB) contains diverse populations

121 Human umbilical cord blood (hUCB)-derived hematopoietic stem c

122 ince the first successful transplantation of umbilical cord blood in 1988, cord blood has become an i

123 tched and one- or two-antigen HLA-mismatched umbilical cord blood in children with acute leukaemia wh

124 Umbilical cord blood is a valuable alternative source of

125 Umbilical cord blood is a valuable alternative source of

126 Although umbilical cord blood is an accepted alternative to bone

127 Umbilical cord blood is an alternative hematopoietic ste

128 URD umbilical cord blood is an alternative HSC source offeri

129 Umbilical cord blood is being compared with other graft

130 s were lower among 13 participants with high umbilical cord blood lead concentrations (>/= 10 mug/dL)

131 ter (aerodynamic diameter </=2.5 microm) and umbilical cord blood leptin and adiponectin levels with

132 In conclusion, metabolomics of umbilical cord blood may identify children at increased

133 hic characteristics and further adjusted for umbilical cord blood mercury or long-chain polyunsaturat

134 Median (25th-75th percentile) maternal and umbilical cord blood metal concentrations, respectively,

135 val was similar to that after transplants of umbilical cord blood mismatched for either one or two an

136 ally sufficient mononuclear cells from human umbilical cord blood (MNC hUCB) were intravenously admin

137 Highly purified umbilical cord blood monocytes cultured with M-CSF and I

138 rrelated with motor improvement, after human umbilical cord blood mononuclear cell (hUCBC) infusion.

139 Transplantation of umbilical cord blood mononuclear cells (UCBMC) promotes

140 T cells from both adult peripheral blood and umbilical cord blood mononuclear cells constitutively ex

141 ipheral blood mononuclear cells and neonatal umbilical cord blood mononuclear cells were collected an

142 HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1)

143 inically, including haploidentical NK cells, umbilical cord blood NK cells, stem cell-derived NK cell

144 son, human BM HDODs-, healthy donor-derived, umbilical cord blood nuclear cells, or CD34(+) cells wer

145 posure and epigenome-wide DNA methylation in umbilical cord blood nucleated cells in Project Viva, a

146 ncentrations of adalimumab and infliximab in umbilical cord blood of newborns and rates of clearance

147 To test this, EPCs isolated from human umbilical cord blood or from adult peripheral blood, and

148 lower-brominated PBDEs were often higher in umbilical cord blood or serum than in maternal samples (

149 ll have a suitable alternative using an URD, umbilical cord blood, or haploidentical-related donors;

150 c sites, such as from the bone marrow, human umbilical cord blood, or skin in vitro.

151 nd gamma-CEHC concentrations in maternal and umbilical cord blood pairs and examined their relations

152 ivery maternal plasma (M2) as well as infant umbilical cord blood plasma (CB).

153 acking a suitable family or unrelated donor, umbilical cord blood provides a promising alternative gr

154 Banked, unrelated umbilical cord blood provides access to hematopoietic st

155 ude that identification of preformed DSAs in umbilical cord blood recipients should be performed and

156 er transplants of two-antigen HLA-mismatched umbilical cord blood (relative risk 2.31, p=0.0003) and

157 man HSPCs were isolated from bone marrow and umbilical cord blood, respectively.

158 In umbilical cord blood samples (n = 101), we measured n-3

159 , as we also identified shared clonotypes in umbilical cord blood samples and all adult repertoires.

160 We collected maternal and umbilical cord blood samples at delivery from 622 mother

161 rmful chemicals in 77 maternal and 65 paired umbilical cord blood samples collected in San Francisco

162 cell mass cytometry of paired peripheral and umbilical cord blood samples from mothers and their neon

163 timated in 282 school-age children from whom umbilical cord blood samples had been obtained and analy

164 Umbilical cord blood samples were obtained at the time o

165 luated by testing paired maternal plasma and umbilical cord blood samples, as well as newborn whole-b

166 els were assessed in 376 paired maternal and umbilical cord blood samples.

167 Haplo and umbilical cord blood SCT allow identification of a donor

168 d donors, haploidentical related donors, and umbilical cord blood stem cell products are frequently u

169 the outcomes of RIC unrelated adult donor or umbilical cord blood stem cell transplantation.

170 peripheral blood-derived stem cells (2; 4%), umbilical cord blood stem cells (2; 4%), allogenic bone

171 Cell has demonstrated dramatic expansion of umbilical cord blood stem cells that promote rapid engra

172 sed mice after they are engrafted with human umbilical cord blood stem cells.

173 (+) and CD4(+)CD161(-) naive Th subsets from umbilical cord blood surprisingly revealed comparable hy

174 span, we show that naive-like MAIT cells in umbilical cord blood switch to a central/effector memory

175 Because umbilical cord blood T cells fail to differentiate towar

176 nine levels in dried blood spots to those in umbilical cord blood to assess cotinine in dried blood s

177 re evolution, analyzing samples ranging from umbilical cord blood to centenarian peripheral blood.

178 f of principle for the utility of allogeneic umbilical cord blood transfusion to treat patients with

179 A 12-month-old boy underwent unrelated donor umbilical cord blood transplant (UCBT) for refractory La

180 Seropositive umbilical cord blood transplant (UCBT) recipients are at

181 Newer strategies such as double umbilical cord blood transplant and utilization of nonmy

182 ection was significantly more frequent after umbilical cord blood transplant and was associated with

183 al T cell pool, such as in newborns or after umbilical cord blood transplant.

184 term clinical outcome in adult recipients of umbilical cord blood transplant.

185 Although double umbilical cord blood transplantation (dUCBT) in adult pa

186 cell alloreactivity is favored after double umbilical cord blood transplantation (dUCBT) in which co

187 virus 6B (HHV-6B) commonly reactivates after umbilical cord blood transplantation (UCBT) and is assoc

188 r transplantation (MMRDT) or unrelated-donor umbilical cord blood transplantation (UCBT) are valuable

189 he state of the art of unrelated donor (URD) umbilical cord blood transplantation (UCBT) for the trea

190 Umbilical cord blood transplantation (UCBT) is an expand

191 Umbilical cord blood transplantation (UCBT) is increasin

192 A disadvantage of umbilical cord blood transplantation (UCBT) is the delay

193 mune reconstitution observed after unrelated umbilical cord blood transplantation (UCBT).

194 causes of morbidity and mortality following umbilical cord blood transplantation (UCBT).

195 sed by Volvariella volvacea following double umbilical cord blood transplantation (UCBT).

196 disease (GVHD) occurs less frequently after umbilical cord blood transplantation (UCBT).

197 , 31 patients with Hurler syndrome underwent umbilical cord blood transplantation and were evaluated

198 such as the marrow failure that occurs after umbilical cord blood transplantation and with aplastic a

199 with metachromatic leukodystrophy underwent umbilical cord blood transplantation at different stages

200 eeply influence NK cell reconstitution after umbilical cord blood transplantation by accelerating the

201 Hematopoietic stem cell and umbilical cord blood transplantation can be a life-savin

202 evel HLA matching who received a single unit umbilical cord blood transplantation for non-malignant d

203 tients with hematological malignancies given umbilical cord blood transplantation from donors carryin

204 Umbilical cord blood transplantation from unrelated dono

205 The results for adult umbilical cord blood transplantation have improved, with

206 Umbilical cord blood transplantation may cure a relevant

207 ernational studies suggested that allogeneic umbilical cord blood transplantation may potentially eme

208 The literature shows that after umbilical cord blood transplantation the relapse rate, d

209 Initially, umbilical cord blood transplantation was limited to chil

210 s may reduce graft-versus-host disease after umbilical cord blood transplantation, but this naivety a

211 In adults, umbilical cord blood transplantation, double umbilical c

212 New investigations include MSC infusions in umbilical cord blood transplantation, MSC therapy for ti

213 In umbilical cord blood transplantation, the ability to fin

214 leukemia, given single-unit, unrelated donor umbilical cord blood transplantation.

215 fect of preformed DSAs on outcomes in double umbilical cord blood transplantation.

216 transplant after autologous, allogeneic and umbilical cord blood transplantation.

217 e of metachromatic leukodystrophy treated by umbilical cord blood transplantation.

218 drome and chronic myelogenous leukemia after umbilical cord blood transplantation.

219 ansplantation for non-malignant diseases-for umbilical cord blood transplantation.

220 T-cell-depleted bone marrow or unmanipulated umbilical cord blood transplantation.

221 ocus has not been well defined for unrelated umbilical-cord blood transplantation.

222 e risk of transplant-related mortality after umbilical-cord-blood transplantation, greater investment

223 o low cell doses restricts the usefulness of umbilical-cord-blood transplantation.

224 a retrospective single-center analysis of 50 umbilical cord blood transplantations UCBTs performed fr

225 1 to 2010, including 37 single and 13 double umbilical cord blood transplantations UCBTs.

226 recipient HLA matching on outcomes of single umbilical-cord blood transplantations for leukaemia and

227 GRFS after umbilical cord blood transplants and marrow from matched

228 were lower after two-antigen HLA-mismatched umbilical-cord-blood transplants (0.54, p=0.0045).

229 ter one-antigen HLA-mismatched low-cell-dose umbilical-cord-blood transplants (1.88, p=0.0455).

230 advanced-stage acute leukemia, and received umbilical cord blood (UCB) allografts.

231 compared the NK responses to influenza using umbilical cord blood (UCB) and adult peripheral blood (A

232 oning (RIC) and transplantation of unrelated umbilical cord blood (UCB) and CD34(+) stem cells from a

233 rks the 20th anniversary of the first use of umbilical cord blood (UCB) as a source of donor cells fo

234 Clinical application of umbilical cord blood (UCB) as a source of hematopoietic

235 ptosis and suppressor cell function of human umbilical cord blood (UCB) CD4+25+ Treg and CD4+25- cell

236 double strand breaks, PFG, and apoptosis in umbilical cord blood (UCB) cells including CD34+ hematop

237 lated donors, and 2 received stem cells from umbilical cord blood (UCB) donors.

238 Umbilical cord blood (UCB) engraftment is in part limite

239 opoietic stem and progenitor cells within an umbilical cord blood (UCB) graft shortens the time to he

240 of single (n = 91) or double (n = 166) unit umbilical cord blood (UCB) grafts after myeloablative (n

241 Umbilical cord blood (UCB) has had considerable impact i

242 We evaluated the efficacy of umbilical cord blood (UCB) in the setting of a nonmyeloa

243 Umbilical cord blood (UCB) is a promising source of stem

244 Umbilical cord blood (UCB) is a valuable source of hemat

245 Unrelated umbilical cord blood (UCB) is an alternative donor sourc

246 Umbilical cord blood (UCB) is an alternative source of h

247 Umbilical cord blood (UCB) is an attractive cell source

248 r, knowledge as to whether FLG expression in umbilical cord blood (UCB) is associated with eczema dev

249 Umbilical cord blood (UCB) is increasingly used as an al

250 Umbilical cord blood (UCB) is one of the first easily av

251 Umbilical cord blood (UCB) is used for HSCT.

252 We recently reported that umbilical cord blood (UCB) monocytes from babies born to

253 Umbilical cord blood (UCB) offers certain advantages ove

254 rgoing in vitro differentiation from CD34(+) umbilical cord blood (UCB) progenitors, LFA-1 expression

255 Previously, we showed that human umbilical cord blood (UCB) regulatory T cells (Tregs) co

256 cells, and plasma preparations prepared from umbilical cord blood (UCB) samples.

257 we show that IL-15 induces NCR expression on umbilical cord blood (UCB) T cells.

258 discuss the recent advances in the field of umbilical cord blood (UCB) transplant (UCBT) for the tre

259 We discuss outcomes after umbilical cord blood (UCB) transplantation (UCBT) for pa

260 Cell dose is a major limitation for umbilical cord blood (UCB) transplantation because units

261 Umbilical cord blood (UCB) transplantation is potentiall

262 Umbilical cord blood (UCB) transplantation is recognized

263 ty and is a common complication after double umbilical cord blood (UCB) transplantation.

264 ematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation.

265 en (HLA)-A, -B, -C, and -DRB1 in 1568 single umbilical cord blood (UCB) transplantations for hematolo

266 One mislabeled umbilical cord blood (UCB) unit was detected on the day

267 or registries of adult volunteers and banked umbilical cord blood (UCB) units provide the potential f

268 Three alternative graft sources, umbilical cord blood (UCB), haploidentical (haplo)-relat

269 mary human T cells from adult peripheral and umbilical cord blood (UCB), thymus and tonsil, although

270 vitro differentiation of NK cells from human umbilical cord blood (UCB)-derived CD34(+) cells.

271 or of activated T cells-1 (NFAT1) protein in umbilical cord blood (UCB)-derived CD4+ T cells and the

272 d clinical outcomes of patients treated with umbilical cord blood (UCB)-derived regulatory T cells (T

273 ffective compared with NK cells derived from umbilical cord blood (UCB).

274 (RD; n = 245), unrelated (URD; n = 100), and umbilical cord blood (UCB; n = 69).

275 Umbilical-cord blood (UCB) is increasingly considered as

276 ntensity conditioning using either unrelated umbilical-cord blood (UCB) or matched-sibling donors (MS

277 r data suggest that the present strategy for umbilical-cord blood unit selection should be reassessed

278 eport the relative efficacy of co-infusing 2 umbilical cord blood units (dUCB) compared with peripher

279 yte antigen match and with the use of double umbilical cord blood units and improved supportive care

280 umbilical cord blood transplantation, double umbilical cord blood units and nonmyeloablative engraftm

281 The standard for selecting unrelated umbilical cord blood units for transplantation for non-m

282 rent practice in that selection of unrelated umbilical cord blood units for transplantation for non-m

283 en comparing patients with DSAs against both umbilical cord blood units to those without DSAs (3-year

284 ents should be performed and that the use of umbilical cord blood units where preformed host DSAs exi

285 or registries of adult volunteers and banked umbilical cord-blood units, such as the Be the Match Reg

286 The selection algorithm for umbilical-cord blood units generally considers intermedi

287 Umbilical cord blood was analyzed for speciated mercury,

288 DNA methylation in umbilical cord blood was associated with maternal serum

289 sma was collected at <26 weeks of gestation; umbilical cord blood was collected at delivery.

290 Umbilical cord blood was obtained from 7 neonates born t

291 engraftment of hematopoietic stem cells from umbilical-cord blood, we observed a new syndrome of cult

292 ) with acute leukaemia and transplanted with umbilical cord blood were compared with outcomes of 282

293 king, mononuclear cells harvested from human umbilical cord blood were grown under proendothelial con

294 ith partially HLA-mismatched unrelated donor umbilical cord blood were studied to investigate the imp

295 Recipients of umbilical cord blood were transplanted with grafts that

296 CD4(+) cells isolated from umbilical cord blood were used to determine detailed kin

297 dren (upper tertile of CPF concentrations in umbilical cord blood) were compared with 20 low-exposure

298 fficiency of nonsense-mediated mRNA decay in umbilical cord blood, which may reflect specific regulat

299 n of caffeine and its primary metabolites in umbilical cord blood with intrauterine growth restrictio

300 ed from the bone marrow, adipose tissue, and umbilical cord blood without altering their ex vivo char